Brendan leads biotherapeutic development and scientific operations at Inhibrx. He oversees multiple groups, including discovery, protein sciences and biology.¬†He has pioneered multiple innovative discovery and optimization platforms. In addition, Brendan has critical responsibilities in corporate strategy execution. Prior to founding Inhibrx, he was a Research Investigator in the biotherapeutics group at the Genomics Institute of the Novartis Research Foundation (GNF). He conducted his graduate research at the Sanford-Burnham-Prebys Medical Discovery Institute. Brendan received his Ph.D. in molecular pathology from the University of California San Diego School of Medicine.